p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy

PURPOSE: To conduct a Phase I trial of a Modified Vaccinia Ankara vaccine delivering wild type human p53 (p53MVA) in combination with gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer. EXPERIMENTAL DESIGN: Patients received gemcitabine on days 1 and 8 and p53MVA vaccine on...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Hardwick, Nicola R, Frankel, Paul, Ruel, Christopher, Kilpatrick, Julie, Tsai, Weimin, Kos, Ferdynand, Kaltcheva, Teodora, Leong, Lucille, Morgan, Robert, Chung, Vincent, Tinsley, Raechelle, Eng, Melissa, Wilczynski, Sharon, Ellenhorn, Joshua D I, Diamond, Don J, Cristea, Mihaela
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856606/
https://ncbi.nlm.nih.gov/pubmed/29301826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2709
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller